Literature DB >> 23804554

Progression in disability and regional grey matter atrophy in relapsing-remitting multiple sclerosis.

Louis Hofstetter1, Yvonne Naegelin, Lukas Filli, Pascal Kuster, Stefan Traud, Renata Smieskova, Nicole Mueller-Lenke, Ludwig Kappos, Achim Gass, Till Sprenger, Iris-Katharina Penner, Thomas E Nichols, Hugo Vrenken, Frederik Barkhof, Chris Polman, Ernst-Wilhelm Radue, Stefan J Borgwardt, Kerstin Bendfeldt.   

Abstract

BACKGROUND: In multiple sclerosis (MS) regional grey matter (GM) atrophy has been associated with disability progression.
OBJECTIVE: The aim of this study was to compare regional GM volume changes in relapsing-remitting MS (RRMS) patients with progressive and stable disability, using voxel-based morphometry (VBM).
METHODS: We acquired baseline and 1-year follow-up 3-dimensional (3D) T1-weighted magnetic resonance imaging (MRI) data of RRMS patients, using two 1.5-Tesla scanners. Patients were matched pair-wise with respect to age, gender, disease duration, medication, scanner and baseline Expanded Disability Status Scale (EDSS) into 13 pairs, with either progressive EDSS (≥ 1 point change y(-1)) or stable EDSS, as well as into 29 pairs with either progressive Multiple Sclerosis Functional Composite (MSFC) at ≥ 0.25% decrease in y(-1) in any component, or stable MSFC. We analysed longitudinal regional differences in GM volumes in the progressive and stable EDSS and MSFC groups, respectively, using VBM.
RESULTS: Significant GM volume reductions occurred in the right precuneus, in the progressive EDSS group. Differential between-group effects occurred in the right precuneus and in the postcentral gyrus. Further longitudinal GM volume reductions occurred in the right orbicular gyrus, in the progressive MSFC group, but no between-group differences were observed (non-stationary cluster-wise inference, all P(corrected) < 0.05).
CONCLUSION: These results suggested a direct association of disability progression and regional GM atrophy in RRMS.

Entities:  

Keywords:  Disability; Expanded Disability Status Scale; Multiple Sclerosis Functional Composite; grey matter atrophy; magnetic resonance imaging; multiple sclerosis; precuneus; relapsing–remitting multiple sclerosis; voxel-based morphometry

Mesh:

Year:  2013        PMID: 23804554      PMCID: PMC6534500          DOI: 10.1177/1352458513493034

Source DB:  PubMed          Journal:  Mult Scler        ISSN: 1352-4585            Impact factor:   6.312


  14 in total

Review 1.  Evidence-based guidelines: MAGNIMS consensus guidelines on the use of MRI in multiple sclerosis-clinical implementation in the diagnostic process.

Authors:  Àlex Rovira; Mike P Wattjes; Mar Tintoré; Carmen Tur; Tarek A Yousry; Maria P Sormani; Nicola De Stefano; Massimo Filippi; Cristina Auger; Maria A Rocca; Frederik Barkhof; Franz Fazekas; Ludwig Kappos; Chris Polman; David Miller; Xavier Montalban
Journal:  Nat Rev Neurol       Date:  2015-07-07       Impact factor: 42.937

Review 2.  MRI in the assessment and monitoring of multiple sclerosis: an update on best practice.

Authors:  Ulrike W Kaunzner; Susan A Gauthier
Journal:  Ther Adv Neurol Disord       Date:  2017-05-12       Impact factor: 6.570

Review 3.  The importance of studying sex differences in disease: The example of multiple sclerosis.

Authors:  Lisa C Golden; Rhonda Voskuhl
Journal:  J Neurosci Res       Date:  2017-01-02       Impact factor: 4.164

4.  Structural abnormalities and altered regional brain activity in multiple sclerosis with simple spinal cord involvement.

Authors:  Ping Yin; Yi Liu; Hua Xiong; Yongliang Han; Shambhu Kumar Sah; Chun Zeng; Jingjie Wang; Yongmei Li
Journal:  Br J Radiol       Date:  2018-01-31       Impact factor: 3.039

5.  Disease-modifying drugs reduce cortical lesion accumulation and atrophy progression in relapsing-remitting multiple sclerosis: results from a 48-month extension study.

Authors:  Francesca Rinaldi; Paola Perini; Matteo Atzori; Alice Favaretto; Dario Seppi; Paolo Gallo
Journal:  Mult Scler Int       Date:  2015-02-23

Review 6.  The Role of T1-Weighted Derived Measures of Neurodegeneration for Assessing Disability Progression in Multiple Sclerosis.

Authors:  Maria A Rocca; Giancarlo Comi; Massimo Filippi
Journal:  Front Neurol       Date:  2017-09-04       Impact factor: 4.003

7.  Evolving role of MRI in optimizing the treatment of multiple sclerosis: Canadian Consensus recommendations.

Authors:  Douglas L Arnold; David Li; Marika Hohol; Santanu Chakraborty; Jeffrey Chankowsky; Katayoun Alikhani; Pierre Duquette; Virender Bhan; Walter Montanera; Hyman Rabinovitch; William Morrish; Robert Vandorpe; François Guilbert; Anthony Traboulsee; Marcelo Kremenchutzky
Journal:  Mult Scler J Exp Transl Clin       Date:  2015-06-10

Review 8.  Outcome Measures in Clinical Trials for Multiple Sclerosis.

Authors:  Caspar E P van Munster; Bernard M J Uitdehaag
Journal:  CNS Drugs       Date:  2017-03       Impact factor: 5.749

9.  Depressive symptoms in multiple sclerosis from an in vivo study with TBSS.

Authors:  Yujuan Shen; Lijun Bai; Ying Gao; Fangyuan Cui; Zhongjian Tan; Yin Tao; Chuanzhu Sun; Li Zhou
Journal:  Biomed Res Int       Date:  2014-05-04       Impact factor: 3.411

Review 10.  The Effect of Disease Modifying Therapies on Disease Progression in Patients with Relapsing-Remitting Multiple Sclerosis: A Systematic Review and Meta-Analysis.

Authors:  Georgios Tsivgoulis; Aristeidis H Katsanos; Nikolaos Grigoriadis; Georgios M Hadjigeorgiou; Ioannis Heliopoulos; Panagiotis Papathanasopoulos; Constantinos Kilidireas; Konstantinos Voumvourakis; Efthimios Dardiotis
Journal:  PLoS One       Date:  2015-12-07       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.